EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review

Eva Hilger iD, Kaitlyn Chan, Alphonsus Yip, Xingyue Maria Wang, Conor Broderick iD, Bernd Arents, Karin van Bart, Kilian Eyerich iD, Joseph Rastrick, Stephan Weidinger, Carsten Flohr iD, BIOMAP Consortium

Journal of the European Academy of Dermatology and Venereology · 2026

DOI: 10.1111/jdv.70330 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2026. Verfasst von Eva Hilger und 11 weiteren Autor:innen. Beteiligte Einrichtung: Unit for Paediatric and Population-Based Dermatology Research, School of Basic and Medical Biosciences, St John's Institute of Dermatology, King's Co…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Biomarkers. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Innovative Medicines Initiative 2 Joint Undertaking (JU).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objectives Atopic dermatitis (AD) is a chronic, inflammatory cutaneous disease characterized by intense itch that affects approximately 20% of children and up to 10% of adults. Our systematic review aims to identify biomarkers with clinical significance for predicting response to systemic therapies and treatment‐related adverse events (AEs) for AD patients. Materials and Methods A systematic search was conducted across the electronic databases Embase and MEDLINE from database inception to September 2024. All records were independently screened at both the title/abstract and full‐text stages. Included articles were randomized controlled trials, cohort studies or case–control studies that reported relevant data for investigating associations between biomarkers and disease progression and/or change in disease activity over time. All discrepancies at any stage were resolved through adjudication by a senior reviewer.

Results

We identified 28 papers evaluating biomarkers for treatment response and 11 for AEs. Across treatment response studies, biomarkers investigated included IgE, eosinophils, LDH, TARC, cytokines, genetic variants and the skin microbiome. Most studies investigated the association between biomarkers and dupilumab, while studies reporting associations between biomarkers and AEs were limited to dupilumab‐related conjunctivitis and ocular surface disease (DAOSD). The primary findings on treatment response were inconsistent, demonstrating that while elevated LDH was associated with poorer response to dupilumab, neither IgE nor eosinophil count showed consistent predictive value. Regarding the association between biomarkers and AEs, IgE was identified as the most promising predictor of DAOSD.

Conclusions

Predicting therapeutic responses and identifying patients at risk of developing AEs will be increasingly important with an expanding range of treatment options for AD. Finding robust predictive biomarkers for AD, however, is complicated by its clinical heterogeneity and multifactorial aetiology. Collaborative projects, such as BIOMAP, hold great potential to advance precision medicine and enhance individualized care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicBiomarkersHumansImmunoglobulin ETreatment OutcomeAntibodies, Monoclonal, HumanizedL-Lactate DehydrogenaseChemokine CCL17EosinophilsCytokines

Stichwörter der Autor:innen

adverse eventsatopic dermatitisbiomarkerseczematreatment response

Substanzen

BiomarkersImmunoglobulin EAntibodies, Monoclonal, HumanizedL-Lactate DehydrogenaseChemokine CCL17dupilumabCytokines

Autor:innen und Institutionen

  • Unit for Paediatric and Population-Based Dermatology Research, School of Basic and Medical Biosciences, St John's Institute of Dermatology, King's College London, London, UK.
  • Dutch Association for People with Atopic Dermatitis, Nijkerk, The Netherlands.
  • Royal College of Physicians, National Guideline Centre, London, UK.
  • Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.
  • Division of Dermatology and Venerology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Immunology Research, New Medicines UCB Pharma, Slough, UK.

ORCID-Profile: Eva Hilger, Conor Broderick, Kilian Eyerich, Carsten Flohr

Förderung

  • Innovative Medicines Initiative 2 Joint Undertaking (JU)

Zitieren

APA

Hilger, E., Chan, K., Yip, A., Wang, X. M., Broderick, C., Arents, B., van Bart, K., Eyerich, K., Rastrick, J., Weidinger, S., Flohr, C., & BIOMAP Consortium (2026). Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70330

Vancouver

Hilger E, Chan K, Yip A, Wang XM, Broderick C, Arents B, et al. Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70330

BibTeX
@article{Hilger2026,
  author = {Hilger, Eva and Chan, Kaitlyn and Yip, Alphonsus and Wang, Xingyue Maria and Broderick, Conor and Arents, Bernd and van Bart, Karin and Eyerich, Kilian and Rastrick, Joseph and Weidinger, Stephan and Flohr, Carsten and BIOMAP Consortium, BIOMAP Consortium},
  title = {Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  doi = {10.1111/jdv.70330}
}
Kostenlos starten →